abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Increase in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 62,733 shares, a growth of 339.8% from the June 30th total of 14,265 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 144,503 shares, the short-interest ratio is presently 0.4 days.

abrdn Life Sciences Investors Stock Performance

Shares of abrdn Life Sciences Investors stock opened at $19.37 on Tuesday. The business has a fifty day simple moving average of $18.57 and a 200-day simple moving average of $17.57. abrdn Life Sciences Investors has a fifty-two week low of $13.01 and a fifty-two week high of $21.32.

abrdn Life Sciences Investors Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st were given a dividend of $0.56 per share. The ex-dividend date was Thursday, May 21st. This represents a $2.24 annualized dividend and a dividend yield of 11.6%.

Institutional Trading of abrdn Life Sciences Investors

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. raised its stake in abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after purchasing an additional 1,529 shares during the period. Global Retirement Partners LLC raised its holdings in abrdn Life Sciences Investors by 187.8% in the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after acquiring an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in abrdn Life Sciences Investors during the 4th quarter valued at approximately $177,000. Evolve Private Wealth LLC bought a new stake in shares of abrdn Life Sciences Investors in the fourth quarter valued at approximately $199,000. Finally, Independent Financial Group LLC acquired a new position in shares of abrdn Life Sciences Investors during the first quarter valued at about $211,000. 32.21% of the stock is currently owned by institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.